Langloh N
Eur J Rheumatol Inflamm. 1983;6(1):84-9.
18,888 patients with chronic or extra-articular rheumatic diseases were treated for an average period of 36.1 or 26.9 days with the new non-steroidal anti-rheumatic agent piroxicam. In particular, piroxicam had a positive effect in terms of providing relief from pain. Side effects were relatively rare and seldom required discontinuation of treatment. In about 75% of the patients the maintenance dose was 20 mg piroxicam in a single daily dose. No influence on the laboratory values or accompanying diseases were observed.
18888例慢性或关节外风湿性疾病患者接受了新型非甾体类抗风湿药吡罗昔康治疗，平均疗程为36.1天或26.9天。特别是，吡罗昔康在缓解疼痛方面有积极作用。副作用相对较少，很少需要停药。约75%的患者维持剂量为每日单次服用20mg吡罗昔康。未观察到对实验室检查值或伴发疾病有影响。
